Charles River Laboratories International (NYSE:CRL) Given New $160.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. raised its target price for Charles River Laboratories International from $145.00 to $160.00, indicating a potential upside of 6.78% from the current stock price.
• Other research firms have varying opinions on the stock, with Mizuho lowering its price target to $155.00 while Barclays increased theirs to $165.00.
• Charles River Laboratories reported $3.12 earnings per share for the last quarter, exceeding expectations and reflecting a 0.6% year-over-year revenue increase.

Charles River Laboratories International (NYSE:CRL - Free Report) had its price target lifted by JPMorgan Chase & Co. from $145.00 to $160.00 in a research note published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the medical research company's stock.

Several other equities analysts have also recently weighed in on CRL. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $150.00 to $200.00 in a report on Wednesday, July 9th. Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Robert W. Baird upped their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Barclays boosted their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a report on Thursday. Finally, Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their target price for the company from $188.00 to $182.00 in a report on Friday, May 23rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $175.69.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded up $0.01 during trading on Thursday, hitting $148.75. 909,836 shares of the stock were exchanged, compared to its average volume of 961,128. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock's fifty day moving average is $155.83 and its 200 day moving average is $149.00. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $230.02. The stock has a market cap of $7.32 billion, a PE ratio of -111.84, a P/E/G ratio of 4.74 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The company's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 1,040 shares of company stock worth $152,423 in the last three months. Insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRL. Exchange Traded Concepts LLC lifted its holdings in shares of Charles River Laboratories International by 1.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company's stock worth $871,000 after acquiring an additional 76 shares during the last quarter. Two Sigma Securities LLC grew its position in Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares during the last quarter. Wahed Invest LLC lifted its stake in shares of Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock worth $244,000 after purchasing an additional 81 shares during the period. Brooklyn Investment Group raised its stake in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after acquiring an additional 86 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its stake in Charles River Laboratories International by 1.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company's stock worth $1,072,000 after acquiring an additional 86 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).